To determine the receptors involved in prostate tumor cell recognition and their contribution, IL-2/IL-15-activated PBMCs from healthy donors were pre-incubated with blocking antibodies against each NK cell receptor, and then used in CD107 degranulation assay against prostate cell lines or K562 as positive control. Here, KLRD1 is linked to prostate neoplasm.